echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > With good policy, these two drug markets are in a golden age of opportunity

    With good policy, these two drug markets are in a golden age of opportunity

    • Last Update: 2020-11-17
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    "Pharmaceutical Network Market Analysis" Recently, the National Health and Health Commission issued the "Exploring the special services for the prevention and treatment of depression" and "Exploring the special services for the prevention and treatment of Alzheimer's disease work programme."
    medical institutions to explore special services for the prevention and treatment of depression and Alzheimer's disease.
    , according to the requirements, by 2022 the rate of depression visits on the existing basis to increase by 50%, treatment rate increased by 30%.
    the recognition rate of depression by doctors in non-psychiatric hospitals should be increased by 50% on the existing basis, and the standard treatment rate should be increased by 20% on the existing basis.
    the two drug markets ushered in a golden opportunity in the prevention and treatment of Alzheimer's disease, the Program requires that by 2022, in the pilot areas, the public awareness of alzheimer's disease prevention and treatment increased to 80%.
    to establish and improve the network of Alzheimer's prevention and treatment services, prevention and treatment service capacity significantly improved, establish and improve patient self-management, family management, community management, hospital management combined prevention intervention model, community (village) elderly cognitive function screening rate of 80%.
    antidepressants market size will exceed 10 billion yuan industry believes that the above-mentioned policies will undoubtedly stimulate the further development of the corresponding market.
    Because, according to the World Health Organization, depression is currently the world's fourth-largest burden of disease and one of the leading causes of functional disability, with a global incidence of depression of about 11%, and about 340 million people worldwide suffering from depression, about one in seven people will suffer from depression at some point in their lives.
    , according to the data show that the existing depression patients nearly 100 million people, accounting for 7.3% of the total population, as a highly disabling disease, depression has become a major public health problem in China.
    that by 2030, depression disorders will be among the top diseases in China.
    Industry estimates that with the acceleration of China's development process, a variety of social contradictions, people's life pressure increased, the incidence of depression continues to rise, as well as the growing demand for therapeutic drugs, the total size of the domestic antidepressant drug market is expected to be close to 10 billion yuan.
    the current market size of less than 8.5 billion yuan, its development potential will be very large.
    the use of Alzheimer's drugs will exceed 30 billion, according to the International Alzheimer's Association, there are currently about 48 million patients worldwide, with one new case added every three seconds.
    In China, the number of people with Alzheimer's disease (Alzheimer's disease) is now close to 10 million, and as the population ages, the number of patients is expected to reach 40 million by 2050, with the drug use amounting to more than 30 billion yuan.
    In fact, in medicine, Alzheimer's is like a difficult climb to climb, because its pathogenesis is unclear, the cause is unusually complex, coupled with the long course of the disease and the hidden disease, which brings a very high risk and failure rate for the development of new drugs, and thus makes Alzheimer's the world's most expensive treatment of diseases.
    despite the difficult progress, some drug companies are still researching Alzheimer's disease (Alzheimer's disease) in order to develop a huge market of tens of billions of dollars a year.
    , for example, last year's approval of China's independent research and development of the "nine phase one" is the result of continuous research by pharmaceutical companies.
    although there is still some controversy, but in the eyes of the industry, the nine-phase one "in the future under the policy-good trend or will be the first to usher in the good."
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.